If fully implemented, Option A averts 391 infections fewer than Options B and B+ and has a generalised cost-effectiveness ratio of $ 844 per infection averted; Option B, a generalised cost-effectiveness ratio of $1,331 per infection averted and Option B+ a generalised cost-effectiveness ratio of US$ 1,265 (from savings attributable to not carrying out CD4 testing). The gene discussed is CD4; the disease is infection.